GlassScriptPhysician profile
Divine Ribakare
NPI 1932441680
$1,723.99
in general payments reported to CMS, 2019-2025
19 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $195 · 2021: $480 · 2022: $46.74 · 2023: $140 · 2024: $214 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.97 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $210.71 | 2020-2021 | |
| Horizon Therapeutics Plc | $203.26 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $189.40 | 2019-2025 | Lokelma |
| Fresenius USA Marketing, INC. | $144.12 | 2020-2025 | Liberty Select Cycler |
| Calliditas Therapeutics US INC. | $139.71 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $132.90 | 2019-2022 | |
| Vantive US Healthcare LLC | $128.68 | 2025 | Renal - Pd |
| Baxter Healthcare | $125.00 | 2024 | |
| Amgen INC. | $114.48 | 2019-2024 | Tavneos |
| Janssen Pharmaceuticals, INC | $105.19 | 2019 | |
| Akebia Therapeutics INC | $52.69 | 2021 | |
| Travere Therapeutics, INC. | $32.26 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $32.15 | 2019-2020 | |
| Exthera Medical Corporation | $29.88 | 2021 | |
| Vifor Pharma, INC. | $20.59 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2021 | |
| Novo Nordisk INC | $15.46 | 2025 | Ozempic |
| Mallinckrodt Enterprises LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divine Ribakare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.